Hazard Information | Back Directory | [Uses]
Pritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research[1][2]. | [in vivo]
Pritumumab is effective in preventing tumor growth in nude mice but not in SCID mice[1].
Pritumumab can limit the growth of xenograft glioma tumors in vivo only in the presence of intact cell-mediated immunity[1]. | [References]
[1] Santosh Kesari, et al. Pritumumab binding to glioma cells induces ADCC and inhibits tumor growth. ASCO Annual Meeting I. 2017. [2] Hugwil AV. The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human × human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy. Med Hypotheses. 2013 Sep;81(3):489-95. DOI:10.1016/j.mehy.2013.05.037 |
|
Company Name: |
Biolab Reagents
|
Tel: |
18108604356 18108604356 |
Website: |
www.biolabreagent.com/ |
Company Name: |
Cell Sciences
|
Tel: |
9785721070 |
Website: |
www.cellsciences.com |
Company Name: |
Wonda Science
|
Tel: |
+1 (514) 581-6866 |
Website: |
www.wondascience.com |
|